Close menu




DEFENCE THERAPEUTICS INC

Photo credits: pixabay.com

Commented by Fabian Lorenz on June 23rd, 2022 | 11:35 CEST

Takeover fantasy: +50% in Valneva shares, and what are BioNTech and Defence Therapeutics doing?

  • Biotechnology
  • Pharma

Tension is rising in the biotech sector as the takeover merry-go-round spins faster and has now hit Valneva. Pfizer's entry caused the stock to explode 50% in three trading days. Earlier, Pfizer had announced it would acquire migraine specialist Biohaven for USD 11.6 billion. Other pharmaceutical giants are also active: Halozyme wants to swallow Antares Pharma, a specialist in urology and endocrinology, for USD 960 million. The acquisition of Sierra Oncology is costing GlaxoSmithKline around USD 1.9 billion. Like Valneva, Defence Therapeutics is about to start important trials and could attract a major partner. A takeover of BioNTech is unlikely, but the flagship German biotech should also benefit from improved sentiment in the industry. The coming week should be operationally exciting for shareholders.

Read

Commented by Armin Schulz on June 17th, 2022 | 10:45 CEST

BioNTech, Defence Therapeutics, Formycon - Biotech stocks with a lot of future potential

  • Biotechnology

A look at the NASDAQ Biotechnology Index shows that the big hype on biotech companies seems to be over for now. Since September 2021, the index has been falling, repeatedly marking new lows. However, this decline can also be seen as an opportunity because the long-term prospects for the industry are good. People are getting older, and with age comes the diseases that want to be fought. Today we look at three companies with a lot of potential for the future.

Read

Commented by Carsten Mainitz on June 8th, 2022 | 11:35 CEST

Valneva, Defence Therapeutics, Bayer - Blockbusters: Turbos for your share portfolio!

  • Biotechnology
  • Vaccination

Blockbusters are drugs with which companies generate sales of more than USD 1 billion per year. Corona vaccines are currently an integral part of the global hit list. But also many application areas in different cancer fields or cardiovascular diseases offer a large market worth billions. Like BioNTech, a company with the right pipeline and the resulting compounds can quickly evolve from a start-up into an established and profitable player.

Read

Commented by Stefan Feulner on May 23rd, 2022 | 13:01 CEST

BioNTech, Monkeypox, Defence Therapeutics, Valneva - Is the next threat coming after Corona?

  • Biotechnology
  • Monkeypox

The Corona pandemic is not over yet, but we should already prepare for future viruses. The next pandemic will come. When it will come is uncertain, and so is which pathogen will we have to deal with. Monkeypox is now spreading globally, and there are already the first cases in Germany. We find out what is known so far, where the dangers lie and what opportunities there are for the biotechnology sector from Dr Moutih Rafei, a renowned pharmacologist and head of research and development at the innovative company Defence Therapeutics Inc.

Read

Commented by Nico Popp on May 18th, 2022 | 12:53 CEST

Big percentages thanks to platform strategy: Amazon.com, Defence Therapeutics, Nordex

  • Biotech

A central principle of the platform economy is to bring together different user groups and thus create synergies. What sounds a bit dry quickly becomes interesting, especially from an investor's point of view. For example, when different car models are based on one and the same platform, or when several diseases can be effectively combated thanks to one and the same technology. The unique aspect for investors: If these synergies come to fruition and a business succeeds in scaling, high returns are possible. We cite three stocks as examples.

Read

Commented by Juliane Zielonka on May 10th, 2022 | 12:38 CEST

Biotech stocks: Defence Therapeutics, BioNTech, BASF - Advantage through platform technology

  • Biotechnology

Large corporations such as BASF were previously considered safe portfolio investments. But the war in Ukraine is throwing a spanner in the works. Force majeure, such as war, can cause deals to fall through without the responsibility of the companies involved. How should investors react now? Which portfolio strategy can keep up with the high volatility of the markets? Newcomers like BioNTech face oversupply and have to accept shortages. A focus on emerging markets seems to be the solution for their growth strategy. But there are subtle differences in the vaccines business, as Defence Therapeutics proves.

Read

Commented by André Will-Laudien on May 2nd, 2022 | 13:27 CEST

BioNTech, Defence Therapeutics, Valneva, MorphoSys - Biotech stocks that will still be fun tomorrow!

  • Biotechnology

One of the most churned areas on the growth stock market is the biotech sector. There was too much disappointment on the drug development side; even in the COVID sector, only a few winners remain. However, the current sell-off could turn out to be an entry opportunity in the medium term because there are more and more people on earth and, fortunately, they are getting older and older; even the Corona pandemic is not likely to change this. There are already 1 billion people worldwide over the age of 60, and forecasts predict that this figure will rise to 2 billion by 2050 - with a total population of more than 9 billion people predicted at that time. Which values have been unjustly neglected, and where are the current opportunities for investors?

Read

Commented by Nico Popp on April 27th, 2022 | 11:54 CEST

Where the sentiment is right: BioNTech, Defence Therapeutics, Amazon

  • Biotechnology

If you want to sell air mattresses in November, you will not succeed even with huge discounts. It is a similar story when selecting stocks. In order to reap returns, investors need to assess the market and bet on the stocks that will be in demand in the near future. In the case of vaccine stocks, the air seemed to be out recently. But now, there are growing indications that more vaccine doses may be needed. We take a look at the sentiment of three stocks.

Read

Commented by Stefan Feulner on April 19th, 2022 | 12:10 CEST

Bayer, Defence Therapeutics, Formycon - Biotech stocks facing transformation

  • Biotechnology

The pharmaceutical industry proved to be a key industry in the Corona pandemic, developing tests, vaccines and drugs at record speed and making them available in large quantities. In the process, biotechnology emerged as the innovative engine. The development of new compounds is particularly important for the pharmaceutical industry, as patent protection for many blockbuster drugs will expire in the future or has already expired. For this reason, the pharmaceutical industry is now entering biotechs much more frequently in the early development phases of a new drug. As a result, early-stage development companies already offer opportunities for multiplication.

Read

Commented by André Will-Laudien on April 1st, 2022 | 12:43 CEST

BioNTech, Defence Therapeutics, Valneva, CureVac - Stocks with blockbuster potential!

  • Biotechnology

With the Ukraine crisis, international vaccination activity has taken a back seat. The world's northern hemisphere is gearing up for next summer, so flu diseases are also slowly taking a back seat. However, the COVID virus will likely continue to mutate over the summer and will reappear in a new guise in the fall. Germany's maximum vaccination rate of 76% has been reached, with just under a quarter of the population ultimately foregoing vaccination after lengthy public measures. For the major biotech companies, it is now a case of - The country needs new products! There are still many areas of application in the field of mRNA. Which stocks stand out with their pipeline?

Read